Haemonetics (NYSE:HAE) Receives “Outperform” Rating from Barrington Research

Barrington Research reaffirmed their outperform rating on shares of Haemonetics (NYSE:HAE) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $86.00 price objective on the medical instruments supplier’s stock.

Several other equities analysts also recently commented on the stock. Raymond James Financial downgraded shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $105.00 to $78.00 in a report on Monday, August 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a report on Wednesday, June 25th. Citigroup decreased their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $68.00 price objective (down from $84.00) on shares of Haemonetics in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $75.89.

Haemonetics Price Performance

Shares of HAE opened at $51.20 on Tuesday. The company has a market cap of $2.47 billion, a price-to-earnings ratio of 15.66, a PEG ratio of 0.93 and a beta of 0.37. Haemonetics has a 1-year low of $47.31 and a 1-year high of $94.99. The company’s fifty day simple moving average is $51.83 and its 200 day simple moving average is $62.55. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, research analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of Haemonetics in the first quarter valued at about $468,000. AQR Capital Management LLC lifted its position in Haemonetics by 591.6% during the first quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock worth $10,931,000 after purchasing an additional 149,325 shares during the period. Envestnet Asset Management Inc. lifted its position in Haemonetics by 16.0% during the first quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier’s stock worth $3,543,000 after purchasing an additional 7,678 shares during the period. Royal Bank of Canada lifted its position in Haemonetics by 2.3% during the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after purchasing an additional 24,650 shares during the period. Finally, Invenomic Capital Management LP bought a new stake in Haemonetics during the first quarter worth about $6,783,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.